论文部分内容阅读
目的分析研究孟鲁司特钠治疗支气管哮喘的临床价值及有效性。方法回顾性分析2011年6月-2011年12月期间在我院治疗的86例支气管哮喘患者的临床资料。86例患者随机分为治疗组和对照组各43例,治疗组给予孟鲁司特钠治疗,对照组给予二丙酸倍氯米松治疗,疗程6周。观察2组临床疗效及不良反应。结果治疗6周后两组哮喘症状评分、PEF、FEV1均得以改善,且治疗组改善更明显(P<0.05);治疗组的总有效率(88.37%)明显高于对照组(79.07%),两组比较差异有统计学意义(P<0.05)。结论孟鲁司特在治疗支气管哮喘中能够明显改善患者的肺功能和临床症状,且不良反应少,疗效显著,是一种安全有效的治疗方法,值得临床推广应用。
Objective To study the clinical value and effectiveness of montelukast sodium in the treatment of bronchial asthma. Methods The clinical data of 86 patients with bronchial asthma treated in our hospital from June 2011 to December 2011 were analyzed retrospectively. Eighty-six patients were randomly divided into treatment group and control group, 43 cases in each group. The treatment group received montelukast sodium, while the control group received beclomethasone dipropionate for 6 weeks. The clinical efficacy and adverse reactions in 2 groups were observed. Results After 6 weeks of treatment, the scores of asthma symptoms, PEF and FEV1 in both groups were improved, and the improvement in the treatment group was more obvious (P <0.05). The total effective rate (88.37%) in the treatment group was significantly higher than that in the control group (79.07% The difference between the two groups was statistically significant (P <0.05). Conclusion Montelukast can significantly improve pulmonary function and clinical symptoms in patients with bronchial asthma with less adverse reactions and significant curative effects. It is a safe and effective treatment and is worthy of clinical application.